Citations (90)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (42)
Adriana Petrazzuolo, M. Chiara Maiuri, Laurence Zitvogel, Guido Kroemer & Oliver Kepp. (2022) Trial Watch: combination of tyrosine kinase inhibitors (TKIs) and immunotherapy. OncoImmunology 11:1.
Read now
Read now
Julie Le Naour, Laurence Zitvogel, Lorenzo Galluzzi, Erika Vacchelli & Guido Kroemer. (2020) Trial watch: STING agonists in cancer therapy. OncoImmunology 9:1.
Read now
Read now
Julie Le Naour, Lorenzo Galluzzi, Laurence Zitvogel, Guido Kroemer & Erika Vacchelli. (2020) Trial watch: TLR3 agonists in cancer therapy. OncoImmunology 9:1.
Read now
Read now
Jenny Sprooten, Jolien Ceusters, An Coosemans, Patrizia Agostinis, Steven De Vleeschouwer, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi & Abhishek D. Garg. (2019) Trial watch: dendritic cell vaccination for cancer immunotherapy. OncoImmunology 8:11.
Read now
Read now
Sarah Lévesque, Jonathan G. Pol, Gladys Ferrere, Lorenzo Galluzzi, Laurence Zitvogel & Guido Kroemer. (2019) Trial watch: dietary interventions for cancer therapy. OncoImmunology 8:7.
Read now
Read now
Lucillia Bezu, Oliver Kepp, Giulia Cerrato, Jonathan Pol, Jitka Fucikova, Radek Spisek, Laurence Zitvogel, Guido Kroemer & Lorenzo Galluzzi. (2018) Trial watch: Peptide-based vaccines in anticancer therapy. OncoImmunology 7:12.
Read now
Read now
Jonathan G. Pol, Sarah Lévesque, Samuel T. Workenhe, Shashi Gujar, Fabrice Le Boeuf, Derek R. Clements, Jean-Eudes Fahrner, Laetitia Fend, John C. Bell, Karen L. Mossman, Jitka Fucikova, Radek Spisek, Laurence Zitvogel, Guido Kroemer & Lorenzo Galluzzi. (2018) Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors. OncoImmunology 7:12.
Read now
Read now
Elena García-Martínez, Melody Smith, Aitziber Buqué, Fernando Aranda, Francisco Ayala de la Peña, Alejandra Ivars, Manuel Sanchez Cánovas, Ma Angeles Vicente Conesa, Jitka Fucikova, Radek Spisek, Laurence Zitvogel, Guido Kroemer & Lorenzo Galluzzi. (2018) Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy. OncoImmunology 7:6.
Read now
Read now
Xinmeng Qi, Bo Jia, Xue Zhao & Dan Yu. (2017) Advances in T-cell checkpoint immunotherapy for head and neck squamous cell carcinoma. OncoTargets and Therapy 10, pages 5745-5754.
Read now
Read now
Mariona Cabo, Rienk Offringa, Laurence Zitvogel, Guido Kroemer, Aura Muntasell & Lorenzo Galluzzi. (2017) Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications. OncoImmunology 6:12.
Read now
Read now
Sabrina Sapski, Nadine Beha, Roland Kontermann & Dafne Müller. (2017) Tumor-targeted costimulation with antibody-fusion proteins improves bispecific antibody-mediated immune response in presence of immunosuppressive factors. OncoImmunology 6:12.
Read now
Read now
Sina Fellermeier, Nadine Beha, Jan-Erik Meyer, Sarah Ring, Stefan Bader, Roland E. Kontermann & Dafne Müller. (2016) Advancing targeted co-stimulation with antibody-fusion proteins by introducing TNF superfamily members in a single-chain format. OncoImmunology 5:11.
Read now
Read now
Laura Mondragón, Guido Kroemer & Lorenzo Galluzzi. (2016) Immunosuppressive γδ T cells foster pancreatic carcinogenesis. OncoImmunology 5:11.
Read now
Read now
Erika Vacchelli, Norma Bloy, Fernando Aranda, Aitziber Buqué, Isabelle Cremer, Sandra Demaria, Alexander Eggermont, Silvia Chiara Formenti, Wolf Hervé Fridman, Jitka Fucikova, Jérôme Galon, Radek Spisek, Eric Tartour, Laurence Zitvogel, Guido Kroemer & Lorenzo Galluzzi. (2016) Trial Watch: Immunotherapy plus radiation therapy for oncological indications. OncoImmunology 5:9.
Read now
Read now
Aitziber Buqué, Norma Bloy, Fernando Aranda, Isabelle Cremer, Alexander Eggermont, Wolf Hervé Fridman, Jitka Fucikova, Jérôme Galon, Radek Spisek, Eric Tartour, Laurence Zitvogel, Guido Kroemer & Lorenzo Galluzzi. (2016) Trial Watch—Small molecules targeting the immunological tumor microenvironment for cancer therapy. OncoImmunology 5:6.
Read now
Read now
Guido Kroemer, Lorenzo Galluzzi & Laurence Zitvogel. (2016) STAT3 inhibition for cancer therapy: Cell-autonomous effects only?. OncoImmunology 5:5.
Read now
Read now
Ornella Franzese, Belinda Palermo, Cosmo Di Donna, Isabella Sperduti, Virginia Ferraresi, Helena Stabile, Angela Gismondi, Angela Santoni & Paola Nisticò. (2016) Polyfunctional Melan-A-specific tumor-reactive CD8+ T cells elicited by dacarbazine treatment before peptide-vaccination depends on AKT activation sustained by ICOS. OncoImmunology 5:5.
Read now
Read now
Bhushan Dharmadhikari, Meihui Wu, Nur Sharalyn Abdullah, Sakthi Rajendran, Nur Diana Ishak, Emily Nickles, Zulkarnain Harfuddin & Herbert Schwarz. (2016) CD137 and CD137L signals are main drivers of type 1, cell-mediated immune responses. OncoImmunology 5:4.
Read now
Read now
Jonathan Pol, Aitziber Buqué, Fernando Aranda, Norma Bloy, Isabelle Cremer, Alexander Eggermont, Philippe Erbs, Jitka Fucikova, Jérôme Galon, Jean-Marc Limacher, Xavier Preville, Catherine Sautès-Fridman, Radek Spisek, Laurence Zitvogel, Guido Kroemer & Lorenzo Galluzzi. (2016) Trial Watch—Oncolytic viruses and cancer therapy. OncoImmunology 5:2.
Read now
Read now
Erika Vacchelli, Fernando Aranda, Norma Bloy, Aitziber Buqué, Isabelle Cremer, Alexander Eggermont, Wolf Hervé Fridman, Jitka Fucikova, Jérôme Galon, Radek Spisek, Laurence Zitvogel, Guido Kroemer & Lorenzo Galluzzi. (2016) Trial Watch—Immunostimulation with cytokines in cancer therapy. OncoImmunology 5:2.
Read now
Read now
Doraid Alrifai, Debashis Sarker & John Maher. (2016) Prospects for adoptive immunotherapy of pancreatic cancer using chimeric antigen receptor-engineered T-cells. Immunopharmacology and Immunotoxicology 38:1, pages 50-60.
Read now
Read now
Jonathan Pol, Guido Kroemer & Lorenzo Galluzzi. (2016) First oncolytic virus approved for melanoma immunotherapy. OncoImmunology 5:1.
Read now
Read now
Lorenzo Galluzzi, Alexander Eggermont & Guido Kroemer. (2016) Doubling the blockade for melanoma immunotherapy. OncoImmunology 5:1.
Read now
Read now
Guido Kroemer & Lorenzo Galluzzi. (2015) Combinatorial immunotherapy with checkpoint blockers solves the problem of metastatic melanoma—An exclamation sign with a question mark. OncoImmunology 4:7.
Read now
Read now
Guido Kroemer & Lorenzo Galluzzi. (2015) Immunotherapy of hematological cancers: PD-1 blockade for the treatment of Hodgkin's lymphoma. OncoImmunology 4:6.
Read now
Read now
Jens Bedke, Stephan Kruck, Georgios Gakis, Arnulf Stenzl & Peter J Goebell. (2015) Checkpoint modulation - A new way to direct the immune system against renal cell carcinoma . Human Vaccines & Immunotherapeutics 11:5, pages 1201-1208.
Read now
Read now
Norma Bloy, Aitziber Buqué, Fernando Aranda, Francesca Castoldi, Alexander Eggermont, Isabelle Cremer, Catherine Sautès-Fridman, Jitka Fucikova, Jérôme Galon, Radek Spisek, Eric Tartour, Laurence Zitvogel, Guido Kroemer & Lorenzo Galluzzi. (2015) Trial watch: Naked and vectored DNA-based anticancer vaccines. OncoImmunology 4:5.
Read now
Read now
Florine Obrist, Gwenola Manic, Guido Kroemer, Ilio Vitale & Lorenzo Galluzzi. (2015) Trial Watch: Proteasomal inhibitors for anticancer therapy. Molecular & Cellular Oncology 2:2.
Read now
Read now
Jonathan Pol, Erika Vacchelli, Fernando Aranda, Francesca Castoldi, Alexander Eggermont, Isabelle Cremer, Catherine Sautès-Fridman, Jitka Fucikova, Jérôme Galon, Radek Spisek, Eric Tartour, Laurence Zitvogel, Guido Kroemer & Lorenzo Galluzzi. (2015) Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy. OncoImmunology 4:4.
Read now
Read now
Aitziber Buqué, Norma Bloy, Fernando Aranda, Francesca Castoldi, Alexander Eggermont, Isabelle Cremer, Wolf Hervé Fridman, Jitka Fucikova, Jérôme Galon, Aurélien Marabelle, Radek Spisek, Eric Tartour, Laurence Zitvogel, Guido Kroemer & Lorenzo Galluzzi. (2015) Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. OncoImmunology 4:4.
Read now
Read now
Erika Vacchelli, Jonathan Pol, Norma Bloy, Alexander Eggermont, Isabelle Cremer, Wolf Hervé Fridman, Jérôme Galon, Aurélien Marabelle, Holbrook Kohrt, Laurence Zitvogel, Guido Kroemer & Lorenzo Galluzzi. (2015) Trial watch: Tumor-targeting monoclonal antibodies for oncological indications. OncoImmunology 4:1.
Read now
Read now
Lorenzo Galluzzi, Guido Kroemer & Alexander Eggermont. (2014) Novel immune checkpoint blocker approved for the treatment of advanced melanoma. OncoImmunology 3:11.
Read now
Read now
Norma Bloy, Jonathan Pol, Fernando Aranda, Alexander Eggermont, Isabelle Cremer, Wolf Hervé Fridman, Jitka Fučíková, Jérôme Galon, Eric Tartour, Radek Spisek, Madhav V. Dhodapkar, Laurence Zitvogel, Guido Kroemer & Lorenzo Galluzzi. (2014) Trial watch: Dendritic cell-based anticancer therapy. OncoImmunology 3:11.
Read now
Read now
Lisa K Spary, Josephine Salimu, Jason P Webber, Aled Clayton, Malcolm D Mason & Zsuzsanna Tabi. (2014) Tumor stroma-derived factors skew monocyte to dendritic cell differentiation toward a suppressive CD14+ PD-L1+ phenotype in prostate cancer. OncoImmunology 3:9.
Read now
Read now
Norma Bloy, Jonathan Pol, Gwenola Manic, Ilio Vitale, Alexander Eggermont, Jérôme Galon, Eric Tartour, Laurence Zitvogel, Guido Kroemer & Lorenzo Galluzzi. (2014) Trial Watch: Radioimmunotherapy for oncological indications. OncoImmunology 3:9.
Read now
Read now
Therese Liechtenstein, Noemi Perez-Janices, Idoia Blanco-Luquin, Cleo Goyvaerts, Julia Schwarze, Ines Dufait, Alessio Lanna, Mark De Ridder, David Guerrero-Setas, Karine Breckpot & David Escors. (2014) Anti-melanoma vaccines engineered to simultaneously modulate cytokine priming and silence PD-L1 characterized using ex vivo myeloid-derived suppressor cells as a readout of therapeutic efficacy. OncoImmunology 3:7.
Read now
Read now
Fernando Aranda, Erika Vacchelli, Florine Obrist, Alexander Eggermont, Jérôme Galon, Catherine Sautès-Fridman, Isabelle Cremer, Jan Henrik ter Meulen, Laurence Zitvogel, Guido Kroemer & Lorenzo Galluzzi. (2014) Trial Watch. OncoImmunology 3:6.
Read now
Read now
Erika Vacchelli, Fernando Aranda, Florine Obrist, Alexander Eggermont, Jérôme Galon, Isabelle Cremer, Laurence Zitvogel, Guido Kroemer & Lorenzo Galluzzi. (2014) Trial watch. OncoImmunology 3:6.
Read now
Read now
Jonathan Pol, Norma Bloy, Florine Obrist, Alexander Eggermont, Jérôme Galon, Isabelle Cremer, Philippe Erbs, Jean-Marc Limacher, Xavier Preville, Laurence Zitvogel, Guido Kroemer & Lorenzo Galluzzi. (2014) Trial Watch:. OncoImmunology 3:6.
Read now
Read now
Fernando Aranda, Erika Vacchelli, Florine Obrist, Alexander Eggermont, Jérôme Galon, Wolf Hervé Fridman, Isabelle Cremer, Eric Tartour, Laurence Zitvogel, Guido Kroemer & Lorenzo Galluzzi. (2014) Trial Watch. OncoImmunology 3:5.
Read now
Read now
Erika Vacchelli, Fernando Aranda, Alexander Eggermont, Jérôme Galon, Catherine Sautès-Fridman, Isabelle Cremer, Laurence Zitvogel, Guido Kroemer & Lorenzo Galluzzi. (2014) Trial Watch. OncoImmunology 3:3.
Read now
Read now
Gwenola Manic, Florine Obrist, Guido Kroemer, Ilio Vitale & Lorenzo Galluzzi. (2014) Chloroquine and hydroxychloroquine for cancer therapy. Molecular & Cellular Oncology 1:1.
Read now
Read now
Articles from other publishers (48)
Marzieh Norouzian & Soghra Abdi. 2024. Lymphatic System - From Human Anatomy to Clinical Practice [Working Title]. Lymphatic System - From Human Anatomy to Clinical Practice [Working Title].
Joseph Willis, Robert A. Anders, Toshihiko Torigoe, Yoshihiko Hirohashi, Carlo Bifulco, Inti Zlobec, Bernhard Mlecnik, Sandra Demaria, Won-Tak Choi, Pavel Dundr, Fabiana Tatangelo, Annabella Di Mauro, Pamela Baldin, Gabriela Bindea, Florence Marliot, Nacilla Haicheur, Tessa Fredriksen, Amos Kirilovsky, Bénédicte Buttard, Angela Vasaturo, Lucie Lafontaine, Pauline Maby, Carine El Sissy, Assia Hijazi, Amine Majdi, Christine Lagorce, Anne Berger, Marc Van den Eynde, Franck Pagès, Alessandro Lugli & Jérôme Galon. (2023) Multi-Institutional Evaluation of Pathologists’ Assessment Compared to Immunoscore. Cancers 15:16, pages 4045.
Crossref
Crossref
Maria Goulielmaki, Savvas Stokidis, Theodoros Anagnostou, Ioannis F. Voutsas, Angelos D. Gritzapis, Constantin N. Baxevanis & Sotirios P. Fortis. (2023) Frequencies of an Immunogenic HER-2/neu Epitope of CD8+ T Lymphocytes Predict Favorable Clinical Outcomes in Prostate Cancer. International Journal of Molecular Sciences 24:6, pages 5954.
Crossref
Crossref
Karl-Göran Tranberg. (2021) Local Destruction of Tumors and Systemic Immune Effects. Frontiers in Oncology 11.
Crossref
Crossref
Xingzhou Peng, Junjie Wang, Feifan Zhou, Qian Liu & Zhihong Zhang. (2021) Nanoparticle-based approaches to target the lymphatic system for antitumor treatment. Cellular and Molecular Life Sciences 78:12, pages 5139-5161.
Crossref
Crossref
Lorenzo Galluzzi & Abhishek D. Garg. (2021) Immunology of Cell Death in Cancer Immunotherapy. Cells 10:5, pages 1208.
Crossref
Crossref
Bo Lin, Hao Li, Tianwen Zhang, Xin Ye, Hongyu Yang & Yuehong Shen. (2021) Comprehensive analysis of macrophage-related multigene signature in the tumor microenvironment of head and neck squamous cancer. Aging 13:4, pages 5718-5747.
Crossref
Crossref
Izabela Karwacka, Łukasz Obołończyk, Sonia Kaniuka-Jakubowska & Krzysztof Sworczak. (2021) The Role of Immunotherapy in the Treatment of Adrenocortical Carcinoma. Biomedicines 9:2, pages 98.
Crossref
Crossref
Ahmet Yilmaz, Hanwei Cui, Michael A. Caligiuri & Jianhua Yu. (2020) Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy. Journal of Hematology & Oncology 13:1.
Crossref
Crossref
Jing Jin & Qijie Zhao. (2020) Engineering nanoparticles to reprogram radiotherapy and immunotherapy: recent advances and future challenges. Journal of Nanobiotechnology 18:1.
Crossref
Crossref
Jitka Fucikova, Oliver Kepp, Lenka Kasikova, Giulia Petroni, Takahiro Yamazaki, Peng Liu, Liwei Zhao, Radek Spisek, Guido Kroemer & Lorenzo Galluzzi. (2020) Detection of immunogenic cell death and its relevance for cancer therapy. Cell Death & Disease 11:11.
Crossref
Crossref
Sabrina Sapski, Nadine Beha, Roland E. Kontermann & Dafne Müller. (2020) Influence of antigen density and immunosuppressive factors on tumor-targeted costimulation with antibody-fusion proteins and bispecific antibody-mediated T cell response. Cancer Immunology, Immunotherapy 69:11, pages 2291-2303.
Crossref
Crossref
Sameer Deshmukh, Przemysław Jurek, Filip Jelen, Sabina Tabaczar, Tomasz Bakowski, David Carter, Richard Fox, Marta Wawrzyniak & Maciej P. Mazurek. (2020) Pure Biologics – From a Bootstrapped Boutique CRO to an Integrated Drug Discovery Public Company. Technology Transfer and Entrepreneurship 7:1, pages 48-63.
Crossref
Crossref
Sheila Spada & Lorenzo Galluzzi. 2020. Extracellular vesicles. Extracellular vesicles
xv
xviii
.
Peter R. Hoffmann, Fukun W. Hoffmann, Thomas A. Premeaux, Tsuyoshi Fujita, Elisa Soprana, Maddalena Panigada, Glen M. Chew, Guilhem Richard, Pooja Hindocha, Mark Menor, Vedbar S. Khadka, Youping Deng, Lenny Moise, Lishomwa C. Ndhlovu, Antonio Siccardi, Andrew D. Weinberg, Anne S. De Groot & Pietro Bertino. (2019) Multi-antigen Vaccination With Simultaneous Engagement of the OX40 Receptor Delays Malignant Mesothelioma Growth and Increases Survival in Animal Models. Frontiers in Oncology 9.
Crossref
Crossref
Erum Shoeb & Kathleen Hefferon. (2019) Future of cancer immunotherapy using plant virus-based nanoparticles. Future Science OA 5:7.
Crossref
Crossref
David G. Leach, Simon Young & Jeffrey D. Hartgerink. (2019) Advances in immunotherapy delivery from implantable and injectable biomaterials. Acta Biomaterialia 88, pages 15-31.
Crossref
Crossref
Juliane Daßler‐Plenker, Annette Paschen, Bastian Putschli, Stephanie Rattay, Saskia Schmitz, Marion Goldeck, Eva Bartok, Gunther Hartmann & Christoph Coch. (2019) Direct RIG‐I activation in human NK cells induces TRAIL‐dependent cytotoxicity toward autologous melanoma cells. International Journal of Cancer 144:7, pages 1645-1656.
Crossref
Crossref
Paola Bonaventura, Tala Shekarian, Vincent Alcazer, Jenny Valladeau-Guilemond, Sandrine Valsesia-Wittmann, Sebastian Amigorena, Christophe Caux & Stéphane Depil. (2019) Cold Tumors: A Therapeutic Challenge for Immunotherapy. Frontiers in Immunology 10.
Crossref
Crossref
Willemijn Hobo, Tim J. A. Hutten, Nicolaas P. M. Schaap & Harry Dolstra. (2018) Immune checkpoint molecules in acute myeloid leukaemia: managing the double‐edged sword. British Journal of Haematology 181:1, pages 38-53.
Crossref
Crossref
M.C. Pérez Gago, O. Saavedra Santa Gadea & L. de la Cruz-Merino. (2017) Advances in the Immunobiological Therapies for Advanced Melanoma. Actas Dermo-Sifiliográficas (English Edition) 108:8, pages 721-728.
Crossref
Crossref
M.C. Pérez Gago, O. Saavedra Santa Gadea & L. de la Cruz-Merino. (2017) Nuevos avances de tratamiento inmunobiológico en el melanoma avanzado. Actas Dermo-Sifiliográficas 108:8, pages 721-728.
Crossref
Crossref
Yi Shi, Wei-Zhong Wu, An Huo, Wei Zhou & Xiao-Hong Jin. (2017) Isobavachalcone inhibits the proliferation and invasion of tongue squamous cell carcinoma cells. Oncology Letters 14:3, pages 2852-2858.
Crossref
Crossref
Qi-Xiang Li, Gerold Feuer, Xuesong Ouyang & Xiaoyu An. (2017) Experimental animal modeling for immuno-oncology. Pharmacology & Therapeutics 173, pages 34-46.
Crossref
Crossref
Wolfram C.M. Dempke, Klaus Fenchel, Peter Uciechowski & Stephen P. Dale. (2017) Second- and third-generation drugs for immuno-oncology treatment—The more the better?. European Journal of Cancer 74, pages 55-72.
Crossref
Crossref
Laveniya Satgunaseelan, Ruta Gupta, Jason Madore, Noel Chia, Trina Lum, Carsten E. Palme, Michael Boyer, Richard A. Scolyer & Jonathan R. Clark. (2016) Programmed cell death-ligand 1 expression in oral squamous cell carcinoma is associated with an inflammatory phenotype. Pathology 48:6, pages 574-580.
Crossref
Crossref
XIAOHONG JIN & YI SHI. (2016) Isobavachalcone induces the apoptosis of gastric cancer cells via inhibition of the Akt and Erk pathways. Experimental and Therapeutic Medicine 11:2, pages 403-408.
Crossref
Crossref
S. Postel-Vinay, S. Aspeslagh, E. Lanoy, C. Robert, J.-C. Soria & A. Marabelle. (2016) Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies. Annals of Oncology 27:2, pages 214-224.
Crossref
Crossref
Eileen S. Kim, Jennifer E. Kim, Mira A. Patel, Antonella Mangraviti, Jacob Ruzevick & Michael Lim. (2016) Immune Checkpoint Modulators: An Emerging Antiglioma Armamentarium. Journal of Immunology Research 2016, pages 1-14.
Crossref
Crossref
Yi Xia, L. Jeffrey Medeiros & Ken H. Young. (2016) Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1865:1, pages 58-71.
Crossref
Crossref
Yutaka Kawakami, Boryana Popivanova, Sunthamala Nuchsupha, Taeko Hayakawa, Kenta Nakamura, Haruna Nagumo, Ikumi Katano, Tomonari Kinoshita, Kinya Tsubota, Hajime Kamijuku, Naoshi Kawamura, Junichiro Miyazaki, Ryosuke Satomi, Juri Sugiyama, Hiroshi Nishio, Shinobu Noji, Chie Kudo-Saito, Nobuo Tsukamoto, Toshiharu Sakurai, Tomonobu Fujita & Tomonori Yaguchi. 2016. Immunotherapy of Cancer. Immunotherapy of Cancer
349
358
.
Amer Assal, Justin Kaner, Gopichand Pendurti & Xingxing Zang. (2015) Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1. Immunotherapy 7:11, pages 1169-1186.
Crossref
Crossref
Cassian Yee, Greg Lizee & Aaron J. Schueneman. (2015) Endogenous T-Cell Therapy. The Cancer Journal 21:6, pages 492-500.
Crossref
Crossref
Mireia Pelegrin, Mar Naranjo-Gomez & Marc Piechaczyk. (2015) Antiviral Monoclonal Antibodies: Can They Be More Than Simple Neutralizing Agents?. Trends in Microbiology 23:10, pages 653-665.
Crossref
Crossref
L. Apetoh, S. Ladoire, G. Coukos & F. Ghiringhelli. (2015) Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?. Annals of Oncology 26:9, pages 1813-1823.
Crossref
Crossref
Jacob L. Goldberg & Paul M. Sondel. (2015) Enhancing Cancer Immunotherapy Via Activation of Innate Immunity. Seminars in Oncology 42:4, pages 562-572.
Crossref
Crossref
Koen van de Ven & Jannie Borst. (2015) Targeting the T-cell co-stimulatory CD27/CD70 pathway in cancer immunotherapy: rationale and potential. Immunotherapy 7:6, pages 655-667.
Crossref
Crossref
David P. Carbone, David R. Gandara, Scott J. Antonia, Christoph Zielinski & Luis Paz-Ares. (2015) Non–Small-Cell Lung Cancer: Role of the Immune System and Potential for Immunotherapy. Journal of Thoracic Oncology 10:7, pages 974-984.
Crossref
Crossref
Laurence Zitvogel, Lorenzo Galluzzi, Oliver Kepp, Mark J. Smyth & Guido Kroemer. (2015) Type I interferons in anticancer immunity. Nature Reviews Immunology 15:7, pages 405-414.
Crossref
Crossref
Jennifer E. Kim & Michael Lim. (2015) The role of checkpoints in the treatment of GBM. Journal of Neuro-Oncology 123:3, pages 413-423.
Crossref
Crossref
Joseph W. Kim, Yusuke Tomita, Jane Trepel & Andrea B. Apolo. (2015) Emerging immunotherapies for bladder cancer. Current Opinion in Oncology 27:3, pages 191-200.
Crossref
Crossref
David Sánchez-Martín, Morten Dræby Sørensen, Simon Lykkemark, Laura Sanz, Peter Kristensen, Erkki Ruoslahti & Luis Álvarez-Vallina. (2015) Selection strategies for anticancer antibody discovery: searching off the beaten path. Trends in Biotechnology 33:5, pages 292-301.
Crossref
Crossref
A. Wang, H.Y. Wang, Y. Liu, M.C. Zhao, H.J. Zhang, Z.Y. Lu, Y.C. Fang, X.F. Chen & G.T. Liu. (2015) The prognostic value of PD-L1 expression for non-small cell lung cancer patients: A meta-analysis. European Journal of Surgical Oncology (EJSO) 41:4, pages 450-456.
Crossref
Crossref
Miki Tongu, Nanae Harashima, Koji Tamada, Lieping Chen & Mamoru Harada. (2014)
Intermittent chemotherapy can retain the therapeutic potential of anti‐
CD
137 antibody during the late tumor‐bearing state
. Cancer Science 106:1, pages 9-17.
Crossref
Crossref
Lorenzo Galluzzi, Erika Vacchelli, José-Manuel Bravo-San Pedro, Aitziber Buqué, Laura Senovilla, Elisa Elena Baracco, Norma Bloy, Francesca Castoldi, Jean-Pierre Abastado, Patrizia Agostinis, Ron N. Apte, Fernando Aranda, Maha Ayyoub, Philipp Beckhove, Jean-Yves Blay, Laura Bracci, Anne Caignard, Chiara Castelli, Federica Cavallo, Estaban Celis, Vincenzo Cerundolo, Aled Clayton, Mario P. Colombo, Lisa Coussens, Madhav V. Dhodapkar, Alexander M. Eggermont, Douglas T. Fearon, Wolf H. Fridman, Jitka Fučíková, Dmitry I. Gabrilovich, Jérôme Galon, Abhishek Garg, François Ghiringhelli, Giuseppe Giaccone, Eli Gilboa, Sacha Gnjatic, Axel Hoos, Anne Hosmalin, Dirk Jäger, Pawel Kalinski, Klas Kärre, Oliver Kepp, Rolf Kiessling, John M. Kirkwood, Eva Klein, Alexander Knuth, Claire E. Lewis, Roland Liblau, Michael T. Lotze, Enrico Lugli, Jean-Pierre Mach, Fabrizio Mattei, Domenico Mavilio, Ignacio Melero, Cornelis J. Melief, Elizabeth A. Mittendorf, Lorenzo Moretta, Adekunke Odunsi, Hideho Okada, Anna Karolina Palucka, Marcus E. Peter, Kenneth J. Pienta, Angel Porgador, George C. Prendergast, Gabriel A. Rabinovich, Nicholas P. Restifo, Naiyer Rizvi, Catherine Sautès-Fridman, Hans Schreiber, Barbara Seliger, Hiroshi Shiku, Bruno Silva-Santos, Mark J. Smyth, Daniel E. Speiser, Radek Spisek, Pramod K. Srivastava, James E. Talmadge, Eric Tartour, Sjoerd H. Van Der Burg, Benoît J. Van Den Eynde, Richard Vile, Hermann Wagner, Jeffrey S. Weber, Theresa L. Whiteside, Jedd D. Wolchok, Laurence Zitvogel, Weiping Zou & Guido Kroemer. (2014) Classification of current anticancer immunotherapies. Oncotarget 5:24, pages 12472-12508.
Crossref
Crossref
Derek L. Clouthier, Angela C. Zhou & Tania H. Watts. (2014) Anti-GITR Agonist Therapy Intrinsically Enhances CD8 T Cell Responses to Chronic Lymphocytic Choriomeningitis Virus (LCMV), Thereby Circumventing LCMV-Induced Downregulation of Costimulatory GITR Ligand on APC. The Journal of Immunology 193:10, pages 5033-5043.
Crossref
Crossref
V. Grünwald & M. Rickmann. (2014) Arzneitherapie solider TumorenPharmacotherapy of solid tumors. Der Internist 55:10, pages 1220-1227.
Crossref
Crossref
E. Vaccheli, J. Michels, J. Hadoux & J. P. Lotz. (2014) American association for cancer research — AACR congress 2014Congrès de l’association américaine de recherche contre le cancer — AACR 2014. Oncologie 16:7-8, pages 341-366.
Crossref
Crossref